Hasuda

Multiple system atrophy (MSA) is a progressive brain disorder with no established treatment to slow its course. This study is designed to evaluate whether MSA-01, a form of coenzyme Q10 called ubiquinol, can slow the worsening of motor symptoms in people with MSA. Researchers will also assess the safety of MSA-01 compared to a placebo. This is a phase III, randomized, double-blind, placebo-controlled trial involving about 140 participants. Participants will be randomly assigned to receive either MSA-01 or a placebo pill daily for 52 weeks. The study is conducted across multiple centers and includes regular clinic visits to monitor treatment effects and safety. Participants will record their medication use and any side effects in a diary throughout the study period. During the study, participants will have regular safety and efficacy assessments, including evaluations using the Unified Multiple System Atrophy Rating Scale (UMSARS) Part 2 to measure motor impairment changes from the start to Week 52. Researchers will also use other clinical scales and closely monitor safety. The total participation duration is approximately one year, during which the goal is to determine if MSA-01 can slow clinical progression compared to placebo while being safe for patients.